February 16, 2018Download pdf
Urbino, Italy – February 16, 2018 - EryDel SpA (www.erydel.com), a clinical stage biopharmaceutical company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced the appointment of Guenter Reinhold Janhofer, MD, to the position of Chief Medical Officer.
“Guenter brings more than 30 years of experience in drug development to the executive management team at EryDel” said Dr. Benatti (CEO), "His track record of managing global clinical development programs and strategic partnerships, combined with his clinical trial experience that spans all stages of product development, including drug-device combinations, makes Guenter ideally suited to lead our development organization moving forward."
Prior to joining EryDel, Guenter was Chief Medical Officer at BTG, a British Healthcare company and leader in the field of interventional medicine. At BTG, Guenter oversaw the clinical development of several compounds from Phase I to Phase IV, successfully filed two compounds with the FDA and supported the launch of these products in the US following FDA approval. Prior to that, Guenter was Vice President, Global Medical and Scientific Affairs at Merck & Co. Guenter qualified as an MD PhD in Germany and advanced to positions of increasing responsibility within the European medical affairs and clinical development organisations of Merck subsidiaries.
Guenter added "I am thrilled to be joining the company at such a significant juncture and look forward to helping advance its clinical programs bringing innovative new treatments to patients suffering from Ataxia Telangiectasia and other devastating diseases with high unmet medical needs."
About Ataxia Telangiectasia
Ataxia Telangiectasia (AT) is a rare genetic disease caused by biallelic mutations in the ataxia telangiectasia mutated (ATM) gene, for which no established therapy is currently available. ATM encodes a PI3Kinase protein shown to play a pivotal role in response to DNA damage and cell cycle control. Homozygosity for ATM mutations result in a multi-systemic disorder, mainly involving the nervous and immune systems. The major clinical feature of AT is severe progressive neurodegeneration from early infancy. Specific features include progressive ataxia of the trunk and limbs, involuntary movements, oculomotor apraxia, difficulties with speech and swallowing, and delayed peripheral neuropathy. Other clinical features of patients with the classical phenotype include oculocutaneous telangiectasia, immunodeficiency with recurrent respiratory tract infections, radiosensitivity and an increased incidence of cancer.
EryDel SpA is a clinical stage biopharmaceutical company specialized in the development of drugs and diagnostics delivered through red blood cells (RBCs) by using a proprietary medical device technology. The most advanced product, EryDex System (EDS), has potential for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. EDS has received Orphan Drug designation for the treatment of AT both from the FDA and the EMA. A completed pilot Phase II trial in AT patients demonstrated statistically significant efficacy of EDS on both the primary and secondary efficacy measures. An international multi-center, one year Phase III clinical study, ATTeST study, is being conducted.
EryDel has a pipeline of preclinical programs that use its proprietary RBC’s delivery technology for the treatment of other rare diseases.
For further information, please contact: Emanuela Germi at +39 02 36504470 or firstname.lastname@example.org